ArticleJournal of intensive care2026
Association of prolonged pre-intubation high-flow nasal cannula duration with survival and successful V-V ECMO liberation in severe ARDS: a retrospective multicenter study.
Article in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIn patients with severe acute respiratory distress syndrome (ARDS), prolonged invasive mechanical ventilation (IMV) prior to veno-venous extracorporeal membrane oxygenation (V-V ECMO) is a known risk factor for poor outcomes. However, the clinical impact of high-flow nasal cannula (HFNC) duration before intubation remains poorly defined. We examined the association between pre-intubation HFNC duration and clinical outcomes, including survival and ECMO liberation.
methodsThis retrospective multicenter study using the J-CARVE registry analyzed 209 adults with severe ARDS who received HFNC before V-V ECMO (2012-2022). The continuous risk of prolonged HFNC for 60-day in-hospital mortality was evaluated using multivariable logistic regression. Subsequently, patients were stratified into Short (< 3 days) and Long (≥ 3 days) HFNC groups using an exploratory ROC-derived cutoff. Clinical outcomes (60-day in-hospital mortality and successful ECMO liberation) were further analyzed using multivariable Cox and Fine-Gray models.
resultsMultivariable logistic regression identified prolonged HFNC duration (analyzed continuously) as an independent risk factor for 60-day in-hospital mortality (adjusted odds ratio 1.22 per 1-day increase; 95% CI 1.07-1.39; P = 0.0035). Sixty-nine patients (33.0%) were in the Long HFNC group. After adjustment, prolonged HFNC (≥ 3 days) was independently associated with a twofold increase in 60-day in-hospital mortality (adjusted Hazard Ratio 2.27; 95% CI 1.24-4.15; P = 0.008). Furthermore, successful ECMO liberation was significantly lower in the Long HFNC group (adjusted Subdistribution Hazard Ratio 0.68; 95% CI 0.50-0.94; P = 0.018).
conclusionsExtended pre-intubation HFNC duration was associated with increased mortality and impaired lung recovery in severe ARDS. Rather than a direct cause of injury, prolonged HFNC likely serves as a complex prognostic marker reflecting disease trajectory and delayed escalation. Clinicians should recognize prolonged HFNC as a continuous trajectory of accumulating risk, rather than relying solely on IMV duration to guide ECMO initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.